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ARTICLE
Single-Dose and Multiple-Dose Pharmacokinetics
of Vaniprevir in Healthy Men
L Caro1, J de Hoon2, M Depré2, C Cilissen3, J Miller1, W Gao1, D Panebianco1, Z Guo1, SL Troemel1, MS Anderson1, N Uemura1,4,
J Butterton1, J Wagner1,5 and DH Wright1,∗
Vaniprevir is an inhibitor of the hepatitis C virus (HCV) NS3/4A protease. The aim of these double-blind, placebo-controlled phase
I studies was to evaluate the safety and pharmacokinetics of vaniprevir in healthy male volunteers. The primary objective for
both studies was the safety and tolerability of vaniprevir. Single-dose and steady-state pharmacokinetics were also assessed.
In both studies, there was no apparent relationship between the frequency or intensity of adverse events and vaniprevir dose. At
single doses>20mg, the plasma area under the curve (AUC)0– andmaximumconcentration (Cmax) increased in a greater-than-
dose-proportional manner. The geometric mean ratios (GMRs; fed/fasted) were 1.22 and 0.79 for AUC0– and Cmax, respectively.
Following multiple doses, GMR accumulations for AUC0–12h and Cmax (day 14/day 1) ranged from 1.53 to 1.90 and from 1.41 to
1.92, respectively. These data support the use of vaniprevir with peginterferon and ribavirin in patients with HCV infection.
Clin Transl Sci (2017) 00, 1–7; doi:10.1111/cts.12482; published online on yyyy-mm-dd.
Study Highlights
WHAT IS THE CURRENT KNOWLEDGE ON THE TOPIC?
✔ Vaniprevir is a selective inhibitor of the HCV NS3/4A pro-
tease that is approved in Japan for the treatment of chronic
HCV infection in combination with peginterferon+ ribavirin.
WHAT QUESTION DID THIS STUDY ADDRESS?
✔ This study evaluated the safety, tolerability, and PKs of
single and multiple doses of vaniprevir in healthy volun-
teers.
WHAT THIS STUDY ADDS TO OUR KNOWLEDGE
✔ Dose-related increases in vaniprevir exposure occurred
in a greater-than-dose-proportional manner with both sin-
gle and twice-daily dosing. Maximum plasma concentra-
tions were achieved within 1–3 h of dosing and plasma ter-
minal t1/2 was 4–6 h at steady state. Safety assessments
indicate that vaniprevir monotherapy was well-tolerated in
healthy volunteers.
HOW THIS MIGHT CHANGE CLINICAL PHARMACOL-
OGY OR TRANSLATIONAL SCIENCE
✔ These data support the administration of twice-daily
vaniprevir 300 mg with peginterferon and ribavirin for the
treatment of chronic HCV infection in Japanese patients.
Direct-acting antiviral therapies have transformed the treat-
ment of hepatitis C virus (HCV) infection. In this rapidly grow-
ing field, the first-generation protease inhibitors boceprevir1,2
and telaprevir3,4 have been overtaken by all oral interferon-
free and ribavirin-free treatment regimens.5–8 Collectively,
these treatment regimens dramatically extend the therapeu-
tic options available to patients with HCV infection.
Vaniprevir is a rapidly reversible, noncovalent, competi-
tive, selective inhibitor of the HCV nonstructural (NS)3/4A
protease that is approved in Japan for the treatment of
chronic HCV infection in combination with peginterferon +
ribavirin.9,10 In preclinical studies, vaniprevir had excellent
liver exposure across various species, low-nanomolar to
sub-nanomolar potency against genotype (GT)1 and 2 pro-
teases, and potent activity in the HCV replicon system.11,12
A substantial decrease in plasma HCV viral load (>5 logs)
has been reported in an HCV-infected chimpanzee model.13
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In patients with HCV GT1 infection, vaniprevir was well tol-
erated and associated with a dose-related (25 mg twice
daily (b.i.d.) to 500 mg b.i.d.) decrease in HCV RNA of 1.8–
4.6 log10 IU/mL following 1 week of monotherapy.14 Subse-
quent clinical trials have shown the combination of vaniprevir
plus peginterferon and ribavirin to be safe and effective
for treatment-naive and treatment-experienced patients with
HCV GT1 infection.9,10,15–17 The aim of the present phase I
study was to evaluate the safety, tolerability, and pharma-
cokinetics (PKs) of single and multiple doses of vaniprevir in
healthy volunteers.
METHODS
These studies were carried out in accordance with the
Declaration of Helsinki, current guidelines on Good Clini-
cal Practices, and local ethical and legal requirements. All
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subjects provided voluntary written informed consent before
trial entry.
Subjects
All subjects were healthy male volunteers aged 18–50 years
with a body mass index (BMI) 30 kg/m2. All subjects
were in good medical health based on medical history,
physical examination, and laboratory safety tests, showed
no clinically significant abnormality on electrocardiogram
(ECG), and were nonsmokers. Subjects with clinically sig-
nificant disease, including HCV and human immunodefi-
ciency virus infection, or an estimated creatinine clearance
of 80 mL/min were excluded. Subjects were also required
to refrain from using any medications, including prescrip-
tion and nonprescription drugs or herbal remedies, from 2
weeks before the initial dose in each panel of the study until
its conclusion. Anticipated use of any prescription or non-
prescription medication during the study was a criterion for
exclusion.
STUDY DESIGN
Study 1
Protocol 001 was a double-blind, placebo-controlled,
alternating-panel, multiple-period, single-rising-dose study.
Two panels (panel A and panel B) of eight subjects alter-
nately received single-rising oral doses of vaniprevir (n = 6)
or placebo (n = 2). Each panel consisted of five dosing peri-
ods: panel A subjects received vaniprevir single doses of 10,
40, 160, 350, and 825 mg or placebo, and panel B subjects
received vaniprevir single doses of 20, 80, 240, and 550 mg
or placebo. In period 5 of panel B, single-dose vaniprevir
(80 mg) was administered with a high-fat meal (the dose of
vaniprevir was identical in periods 2 and 5 of panel B, ensur-
ing that the same subjects received the vaniprevir dose both
with and without the high-fat meal). A minimum washout
interval of 48 h was observed between dose escalations to
allow for PK sample collection and assessment of adverse
events (AEs). There was also a minimum washout period of
3 days for each subject before receiving the next dose in
the subsequent study period (except for subjects in panel B,
period 5, who observed a 1-week washout period from the
previous dose). After each dose level, safety was reviewed;
the decision to proceed to the next dose level was based on
acceptable safety and tolerability.
Study 2
Protocol 002 was a double-blind, randomized, placebo-
controlled, staggered incremental dose study consisting of
six successive panels (panels A, B, C, D, E, and F). In each
panel, eight subjects were randomized to receive vaniprevir
(n = 6) or placebo (n = 2) in a blinded manner. Subjects in
panels A, B, C, and F received a single dose of vaniprevir
(100, 200, 400, or 800 mg, respectively) or placebo on days
1 and 14, and 2 daily doses of vaniprevir (100, 200, 400, or
800 mg b.i.d., respectively) or placebo on days 2–13. Sub-
jects in panel D received a single dose of vaniprevir 1,000
mg or placebo followed by a 7-day washout period. Then the
subjects in panel D received single doses of vaniprevir 600
mg or placebo on days 1 and 14 and vaniprevir 600 mg b.i.d.
or placebo on days 2–13. Subjects in panel E first received
a single dose of vaniprevir 1,000 mg or placebo (period 1)
followed by a 7-day washout period, then a single dose
of vaniprevir 1,300 mg or placebo (period 2) followed by a
second 7-day washout period, and finally a single dose
of vaniprevir 1,600 mg or placebo (period 3). The adminis-
tration of higher single doses in panel E was designed to
provide experience with sufficiently high total daily expo-
sures that would allow administration of 800 mg b.i.d. in
panel F.
Assessments
Blood samples were obtained to assess the single-dose and
steady-state plasma PKs of vaniprevir. Parameters evaluated
included: area under the plasma concentration vs. time curve
for 12 and 24 h postdose (AUC0–12h and AUC0–24h, respec-
tively) as appropriate on day 1; AUC0–12h on day 14;maximum
concentration of drug in the plasma (Cmax); plasma trough
concentration (Ctrough); time to reach Cmax (tmax); apparent ter-
minal elimination half-life (t½); and accumulation ratio (AR). In
addition, in study 2, AUC extrapolated to infinity (AUC0–)
was calculated from concentration vs. time data collected
following dosing on day 1, for comparison with AUC0–12h
on day 14 of multiple dosing to determine predictability of
multiple-dose PKs from single-dose PKs.
Urine samples for vaniprevir analysis were collected pre-
dose and up to 24 h postdose following administration of
160, 240, and 825-mg single doses in study 1 (periods 3, 4,
and 5). The safety and tolerability of vaniprevir wasmonitored
by clinical assessment of AEs and by repeated measure-
ments of vital signs, physical examinations, 12-lead ECGs,
and standard laboratory safety tests (hematology, chemistry,
and urinalysis).
Analytical methods
Plasma and urine concentrations of vaniprevir were assayed
at Merck & Co., Inc. (Kenilworth, NJ, USA; using high-
performance liquid chromatographic tandem mass spec-
trometry). The drug and internal standard were isolated from
plasma using liquid–liquid extraction in the 96-well format.
The lower limit of quantitation (LLOQ) was 1 ng/mL and the
linear calibration range was 1–1,000 ng/mL.
Data analysis
The primary objective for both studies was to establish the
safety and tolerability of single and multiple dosing with
vaniprevir. The secondary objectives were to determine the
impact of a high-fat meal on vaniprevir PKs relative to
fasted administration (study 1) and whether at least one well-
tolerated, twice-daily dose would result in a day 14 geomet-
ric mean (GM) Ctrough of >25 nM (study 2). A target Ctrough of
25 nM was selected based on preclinical and clinical data
suggesting that a value of 35 nM was an optimal PK target,
with a lower limit of 25 nM.
Safety assessments and clinical and laboratory AEs are
summarized descriptively for placebo and each vaniprevir
dose in both studies. Other safety measurements, such as
laboratory tests, ECG parameters, and vital signs, were eval-
uated following multiple doses of vaniprevir. With the excep-
tion of C12h values, which were obtained using SAS, version
9.1 (SAS, Cary, NC), all PK parameters were calculated
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Table 1 Vaniprevir pharmacokinetics following single oral doses in fed and fasted healthy male subjects
Dosea
(mg)
AUC0–b (nM·h)
n = 6
Cmaxb (nM)
n = 6
C12hb (nM)
n = 6
tmaxc (h)
n = 6
Apparent
terminal t½d (h)
n = 6
A 40 43.24e (34.63–54.00) 22.48 (15.48–32.65) 1.35 (0.64–2.85) 1.00 (1.00–1.50) 3.9 (24.8)
160 432.61 (354.35–528.14) 162.71 (112.03–236.33) 5.06 (3.77–6.80) 1.50 (1.50–2.00) 4.1 (33.6)
350 2,014.47 (1650.51–2458.70) 857.09 (590.11–1,244.86) 11.88 (8.84–15.96) 2.00 (1.50–3.00) 4.5 (22.3)
825 17,061.96 (13,975.65–20,829.83) 6,524.18 (4,491.93–9,475.86) 67.93 (50.54–91.29) 2.00 (2.00–4.00) 4.6 (32.7)
B 80 76.90 (62.27–94.95) 33.24 (22.85–48.35) 1.49 (0.98–2.28) 2.00 (1.00–3.00) 4.3 (23.2)
240 600.32 (479.35–751.83) 233.18 (160.54–338.69) 6.95 (5.17–9.34) 2.00 (1.50–3.00) 4.4 (38.4)
550 4,006.30 (3279.05–4894.84) 1,653.27 (1,138.24–2,401.36) 24.19 (17.99–32.52) 3.00 (2.00–3.00) 5.0 (51.9)
rMSEe 0.144 0.396 0.308
AUC0–, area under the plasma concentration vs. time curve extrapolated to infinity; Cmax, maximum concentration; C12h, plasma concentration at 12 h postdose;
rMSE, root mean square error; tmax, time taken to reach Cmax occurred; t½, elimination half-life.
All doses administered after an 8-h fast.
aAUC0– and apparent terminal t½ values were not calculable for two subjects in the 40-mg dose level, one subject in the 80-mg fasted dose level, and two subjects
in the 240-mg dose level. Vaniprevir plasma concentrations were below the lower limit of quantitation for the 10-mg and 20-mg doses. bBack-transformed least-
squares mean and confidence interval from mixed-effects model performed on natural log-transformed values. cMedian (minimum and maximum) reported for
tmax. dGeometric mean and percent of geometric coefficient of variation reported for apparent terminal t½. erMSE: Square root of conditional mean squared error
(residual error) from the linear mixed effects model. rMSE*100% approximates the within-subject %CV on the raw scale.
from the plasma-concentration-time data using the software
WinNonlin (Pharsight, Mountain View, CA). All AUC parame-
ters were calculated using the linear trapezoidal method for
ascending concentrations and the log trapezoidal method
for descending concentrations. For each subject, the appar-
ent terminal t½ was calculated by regression of the terminal
log-linear portion of the plasma concentration–time profile.
Study 1 (Protocol 001)
The individual AUC0–, Cmax, and C12h values from both pan-
els were natural-log transformed and evaluated using linear
mixed-effects models containing treatment as a fixed effect
and subject as a random effect. For each treatment, 95%
confidence intervals (CIs) for the mean log concentration
were calculated, and the CI limits then back-transformed to
construct the GMs and corresponding 95% CIs on the orig-
inal scale. To evaluate the effect of food on vaniprevir PKs,
geometric mean ratios (GMRs; fed/fasted) and correspond-
ing 90% CIs were constructed for AUC0– and Cmax from
the aforementioned models. Although no formal testing was
performed, appropriate summary statistics were provided for
tmax and apparent terminal t½.
Study 2 (Protocol 002)
Individual AUC0–12h, Ctrough, and Cmax values (except for
panel E) were natural log-transformed and evaluated using
a mixed-effect model with fixed-effects for dose, day, and
dose-by-day interaction, and random effects for subject
within dose. For AUC0–12h, a 90% CI for the mean between-
day difference (day 14/day 1) was calculated for each dose
on the log-scale based on the analysis of variance (ANOVA)
model. The CIs were exponentiated to obtain the 90% CIs
for the AR for each dose. For log-AUC0–12h, log-Ctrough, and
log-Cmax, a 95% CI for each dose level was calculated
based on the ANOVA model. These CIs were exponentiated
to obtain the 95% CIs for GM AUC0–12h, Ctrough, and Cmax.
Day 1 AUC0–24h and AUC0– were log-transformed and
evaluated by an ANOVA model, with dose as the single
factor. The 95% CIs for day 1 GM AUC0–24h and AUC0–
were similarly constructed based on the ANOVA model.
Descriptive statistics are provided for all PK parameters
following single oral doses of vaniprevir (panels D and E), as
well as tmax and apparent terminal t½ from all panels.
For the secondary hypothesis in study 2, the estimated SD
for the natural log-Ctrough was 0.22 nM. For a panel of six
subjects, given a true GM Ctrough of 34 nM, there is 90%
probability that the lower limit of the 90% CI of GM Ctrough
exceeded 25 nM. Given a true GM Ctrough of 32 nM, there
was 80% probability that the lower limit of the 90% CI of
GM Ctrough exceeded 25 nM.
RESULTS
Study 1
Sixteen subjects were enrolled. All subjects were white, with
a mean age of 30.7 years (range, 20–43 years) and a mean
BMI of 23.7 kg/m2 (range, 19.6–27.6 k/m2). All 16 subjects
completed the study and were included in the evaluation of
PK and safety.
Safety
Single oral doses of vaniprevir up to 825 mg were gener-
ally well tolerated in healthy male subjects. Fifteen subjects
reported a total of 72 AEs, of which 23 were considered
related to treatment. The most common clinical AEs (regard-
less of relation to study treatment) were nasopharyngitis
(n = 6), headache (n = 5), and influenza (n = 3). There was
no apparent relationship between the frequency and inten-
sity of AEs and vaniprevir dose, and no consistent, clinically
relevant, treatment-related, or dose-related effects on ECGs,
vital sign measurements, or laboratory safety tests. There
were no serious AEs or laboratory AEs, no subject discon-
tinued because of an AE, and there were no deaths.
Pharmacokinetics
For subjects receiving vaniprevir 10 mg, all vaniprevir plasma
concentrations were below the assay LLOQ except for one
sample. Similarly, at the 20-mg dose, vaniprevir plasma
concentrations were only detectable between 0.5 and 4 h
www.cts-journal.com
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Table 2 Comparison of vaniprevir (80 mg) in fasted and fed subjects (Protocol 001, panel B)
Parametera Vaniprevir, 80 mg fed Vaniprevir, 80 mg fasted Vaniprevir, 80 mg fed/fasted
GM (95% CI) GM (95% CI) GMR (90% CI) rMSEb
AUC0–c 93.97 (75.13–117.55) 76.90 (62.27–94.95) 1.22 (1.02–1.46) 0.144
Cmaxc 26.39 (18.14–38.38) 33.24 (22.85–48.35) 0.79 (0.54–1.17) 0.396
tmaxd 2.00 (1.00–4.00) 2.00 (1.00–3.00)
Apparent terminal t½e (h) 2.3 (32.6) 4.3 (23.2)
AUC, area under the curve; CI, confidence interval; Cmax, maximum concentration; GM, geometric least-squares means; GMR, geometric least-squares mean
ratio (day 14/day 1); rMSE, root mean square error; tmax, time taken to reach Cmax occurred; t½, elimination half-life.
rMSE*100% approximates the within-subject %CV on the raw scale.
aAUC0– and apparent terminal t½ values were not calculable for two fed subjects and one fasted subject. brMSE: Square root of conditional mean squared
error (residual error) from the linear mixed-effects model. cBack-transformed least-squares mean and confidence interval from mixed-effects model performed on
natural-log transformed values. dMedian (min, max) reported for tmax. eGeometric mean and percent of geometric coefficient of variation reported for apparent
terminal t½.
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Figure 1 Mean plasma vaniprevir pharmacokinetic profiles following administration of multiple oral doses in healthy male subjects (n =
6 per dose level). Dosing was daily on days 1 and 14, and twice daily (i.e., every 12 h) on days 2 through 13. Serum concentrations were
below level of assay quantification 24 h after the first dose on day 1 in patients receiving vaniprevir 100 mg.
postdose. Summary statistics and statistical comparisons
were, therefore, not performed for the 10-mg and 20-mg
doses. At higher doses, vaniprevir plasma AUC0– and
Cmax increased in a greater-than-dose-proportional manner
(Table 1). The GM apparent terminal t½ was 4–5 h inde-
pendent of dose, and median tmax ranged from 1–3 h.
Plasma vaniprevir concentrations were detectable up to
12 h following 80-mg dosing in both fasted and fed states.
The GMR (fed/fasted) and 90% CI were 1.22 (1.02–1.46) and
0.79 (0.54–1.17) for AUC0– and Cmax, respectively (Table 2).
Median tmax values were 2 h in fed and fasted patients receiv-
ing the 80-mg dose. Under fed conditions, the apparent ter-
minal t½ GM value for the 80-mg dose was decreased by 2
h as compared with the 80-mg administered fasted.
Urine concentrations of vaniprevir were below LLOQ at
all time points following the 160-mg and 240-mg doses.
Approximately 0.2% of the vaniprevir dose was eliminated
in urine as unchanged drug following the 825-mg dose.
Study 2
Forty-eight healthy male subjects were enrolled. The mean
age of enrolled subjects was 37.1 years (range, 19–48 years),
with a mean BMI of 24.8 kg/m2 (range, 20.2–30.2 kg/m2).
Three subjects discontinued for reasons unrelated to the
study drug (i.e., due to administrative reasons) and 45 sub-
jects completed the study. All 48 subjects were included in
the safety evaluation.
Safety
Forty-two subjects reported a total of 105 AEs, all of which
were of mild or moderate intensity. Twenty-nine AEs were
considered to be related to the study drug by the investiga-
tor. No patient discontinued treatment due to an AE and there
were no serious AEs. No laboratory AE was reported. All AEs
resolved with ongoing treatment, and there was no apparent
relationship between the frequency or intensity of AEs and
the dose of vaniprevir. The most common AEs in patients
receiving single doses were headache (n = 6) and diarrhea
(n = 3), and those in patients receiving multiple doses were
diarrhea (n = 8), abdominal discomfort (n = 4), and nausea
(n = 4). There were no consistent, clinically relevant,
treatment-related, or dose-related effects on ECGs, vital sign
measurements, or laboratory safety tests.
Pharmacokinetics
Accumulation of vaniprevir in the plasma occurred over the
14-day dosing period in all subjects (Figure 1 and Table 3).
The GM ARs for AUC0–12h and Cmax (day 14/day 1) ranged
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Table 3 Summary statistics of plasma vaniprevir pharmacokinetic parameters following multiple oral dosing in healthy male subjects (n = 6 for each panel)
Panel
Dose
(mg) Day AUC0–12ha (nM/h) AUC0–24ha (nM/h) AUC0–a (nM/h) Cmaxa (nM) C12ha (nM) C24ha (nM) tmaxb (h)
Apparent
t1/2c (h)
A 100d 1 199.11
(132.23–299.81)
215.81
(147.61–315.50)
221.48
(147.67–332.18)
8,782.07
(5,855.41–13,171.55)
3.14
(2.18–4.51)
NA 1.00
(0.50–2.00)
4.6 (36.7)
14 332.29
(220.68–500.34)
NA NA 120.92
(75.75–193.02)
6.00
(4.17–8.61)
2.01
(1.35–3.00)
1.50
(0.50–2.03)
5.1 (31.4)
GMR 1.67 (1.35–2.06) NA NA 1.41 (0.97–2.06) 1.91
(1.61–2.28)
NA NA NA
B 200d 1 569.45
(378.18–857.45)
614.88
(420.58–898.93)
635.34
(423.61–952.90)
295.41
(185.05–471.56)
7.08
(4.93–10.18)
2.45
(1.71–3.50)
1.00
(1.00–2.00)
6.5 (28.3)
14 1,083.00
(719.24–1,630.74)
NA NA 498.99
(312.59–796.56)
13.16
(9.16–18.90)
3.20
(2.24–4.57)
1.00
(1.00–2.00)
4.4 (13.2)
GMR 1.90 (1.54–2.35) NA NA 1.69 (1.16–2.47) 1.86
(1.56–2.21)
1.31
(1.08–1.57)
NA NA
C 400d 1 2,171.64
(1,442.23–3,269.97)
2,262.90
(1,547.85–3,308.28)
2,278.27
(1,519.03–3,417.00)
871.18
(545.74–1,390.69)
18.58
(12.93–26.69)
3.03
(2.18–4.19)
1.51
(1.50–2.00)
4.1 (11.6)
14 3,312.76
(2,200.06–4,988.21)
NA NA 1,484.32
(929.84–2,369.47)
25.43
(17.70–36.53)
4.36
(3.15–6.05)
1.50
(1.00–2.00)
3.9 (24.7)
GMR 1.53 (1.24–1.88) NA NA 1.70 (1.17–2.49) 1.37
(1.15–1.63)
1.44
(1.22–1.71)
NA NA
D 600d 1 3,755.34
(2,493.99–5,654.63)
3,912.96
(2,676.51–5,720.61)
3,938.76
(2,626.15–5,907.44)
1,363.86
(854.37–2,177.17)
32.36
(22.53–46.49)
4.95
(3.57–6.86)
2.50
(2.00–3.00)
4.0 (18.5)
14 5,905.16
(3,921.72–8,891.74)
NA NA 2,019.46
(1,265.06–3,223.72)
45.40
(31.61–65.22)
5.80
(4.18–8.03)
2.50
(1.00–4.00)
3.8 (10.6)
GMR 1.57 (1.28–1.94) NA NA 1.48 (1.01–2.16) 1.40
(1.18–1.67)
1.17
(0.99–1.39)
NA NA
F 800d 1 8,511.27
(5,652.48–12,815.92)
8,755.13
(5,988.61–12,799.69)
8,782.07
(5,855.41–13,171.55)
2,909.88
(1,822.85–4,645.13)
54.06
(37.63–77.66)
6.19
(4.47–8.58)
2.00
(2.00–3.00)
3.4 (17.8)
14 14,855.81
(9,866.00–22,369.26)
NA NA 5,583.31
(3,497.59–8,912.81)
62.86
(43.76–90.30)
7.64
(5.46–10.69)
2.00
(2.00–3.00)
5.4 (43.5)
GMR 1.75 (1.42–2.15) NA NA 1.92
(1.31–2.80)
1.16
(0.98–1.38)
1.23
(1.02–1.48)
NA NA
AUC, area under the curve; C12h, plasma concentration at 12 h postdose; C24h, plasma concentration at 24 h postdose; Cmax, maximum concentration; GM,
geometric least-squares means; GMR, geometric least-squares mean ratio (day 14/day 1); NA, not applicable; tmax, time taken to reach Cmax occurred; t½,
elimination half-life.
aBack-transformed least-squares mean and confidence interval from linear mixed effect model performed on natural log-transformed values for the geometric
mean (95% confidence interval) and geometric mean ratio (90% confidence interval). bMedian (range). cGeometric mean and percent of geometric coefficient of
variation reported for t½. dDose was administered daily on days 1 and 14 and twice daily on days 2–13.
from 1.53–1.90 and from 1.41–1.92, respectively. On days
1 and 14, both AUC0–12h and Cmax seemed to increase in a
greater-than-dose-proportional manner at doses >100 mg.
Trough values (C12h) also seemed to increase slightly in a
greater-than-dose-proportional manner on days 1 and 14.
Steady-state levels of vaniprevir were generally achieved on
day 3 in panels A, B, and C (100, 200, and 400 mg, respec-
tively), on day 8 in panel D (600 mg), and on day 4 in panel F
(800 mg). The GM for day 14 C12h was >25 nM following the
600-mg and 800-mg b.i.d. dosing of vaniprevir.
At higher single doses of vaniprevir (1,000 and 1,300 mg),
there was appreciable variability (Figure 2 and Table 4).
Substantially higher exposures were observed following
administration of a single dose of vaniprevir 1,300 mg
compared with lower single doses, confirming the greater-
than-dose-proportional increase in exposures seen at the
lower doses evaluated in study 1. The observed GM
AUC0–12h and Cmax values following single-dose adminis-
tration of vaniprevir 1,000 mg were between 12,518 and
16,505 nM/h and between 3,865 and 5,903 nM, respectively.
Following single-dose administration of vaniprevir 1,300 mg,
the observed geometric AUC0–12h and Cmax were between
24,147 and 32,250 nM/h and between 7,579 and 9,199 nM,
respectively.
Vaniprevir had median tmax values ranging from 1.0–3.5 h
following single and multiple doses (Tables 3 and 4). There
was a trend toward increasing tmax with increasing dose. Fol-
lowing tmax, plasma vaniprevir concentrations declined in a
biphasic manner with GM apparent terminal t½ values of 3.9–
5.0 h and 3.4–6.5 h following single (Table 1) and b.i.d. dos-
ing (Table 3), respectively. Across all single-dose PK data in
the current study, the geometric coefficients of variation for
AUC0– and Cmax ranged from 65–86% and from 69–84%,
respectively.
DISCUSSION
Vaniprevir is a selective inhibitor of the HCV NS3/4A pro-
tease approved, in combination with peginterferon and
ribavirin, in Japan for the treatment of treatment-naive
and treatment-experienced patients with HCV infection.9,10
Previous studies with this agent report potent in vitro activity
in preclinical models11,12 and antiviral activity when used in
www.cts-journal.com
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Figure 2 Mean plasma concentrations of vaniprevir following
administration of single oral doses of vaniprevir.
combination with peginterferon and ribavirin in patients with
HCV infection.15–17 Data from the present studies support
a twice-daily dosing regimen with vaniprevir. Single-dose
administration of vaniprevir 80 mg with a high-fat meal did
not have a clinically meaningful effect on the plasma PKs
of vaniprevir. Therefore, vaniprevir alone can be adminis-
tered without regard to food. However, because vaniprevir
is administered together with ribavirin and peginterferon,
dosing instructions related to administration of peginterferon
and ribavirin with food also apply to vaniprevir combination
treatment.
Dose-related increases in vaniprevir exposure occurred
in a greater-than-dose-proportional manner with both sin-
gle and twice-daily dosing. Maximum plasma concentrations
were achieved within 1–3 h of dosing and plasma terminal
t1/2 was 4–6 h at steady state. With multiple dosing, accu-
mulation was observed with ratios of day 14/day 1 ranging
between 1.5 and 1.9 for AUC and Cmax. Single-dose adminis-
tration does not predict steady-state PKs following multiple-
dose administration, reflecting nonlinear PKs. Vaniprevir is a
substrate of the CYP3A-metabolizing enzyme and the hep-
atic organic anion transporting polypeptide-1B1/3 uptake
transporter. The nonlinear PKs of vaniprevir may be attributed
to saturation of hepatic uptake and/or elimination.18 The
longer time to achieve steady-state relative to the half-life
also suggests saturable distribution and/or elimination of
vaniprevir.
Safety assessments indicate that vaniprevir monother-
apy was well tolerated in healthy volunteers, with mild-to-
moderate headache and gastrointestinal AEs among the
most commonly reported safety events. Increasing dose was
not associated with an increase in AE frequency.
The PK profile observed in healthy subjects is consis-
tent with that observed in Japanese HCV-infected patients
following co-administration of vaniprevir 100, 300, or 600
mg b.i.d. with peginterferon and ribavirin. Similar to what
was seen in healthy subjects, vaniprevir plasma PKs
(i.e., AUC0–12 and Cmax) increased in a greater-than-dose-
proportional manner in Japanese HCV-infected patients.
However, higher exposures were observed in Japanese
vs. non-Japanese HCV-infected patients. In Japanese
patients, the mean steady-state vaniprevir plasma expo-
sure (i.e., AUC0–12) was 3.8, 25.3, and 78.5 μM/h follow-
ing co-administration of 100, 300, or 600 mg b.i.d. of
vaniprevir with peginterferon and ribavirin, respectively.10,19
Vaniprevir has low-to-moderate bioavailability; therefore,
minor physiologic changes (e.g., body weight and liver
size) affecting first-pass processes (e.g., hepatic uptake)
may be contributing to the moderate-to-high vaniprevir PK
variability.20
The trends observed in the present PK data in healthy
subjects are generally similar to those reported previously
in patients with HCV infection, both when administered as a
monotherapy14 and when used in combination with peginter-
feron and ribavirin.15 When administered as monotherapy in
Table 4 Mean summary statistics of plasma vaniprevir pharmacokinetic parameters following administration of single oral doses (1,000 and 1,300 mg) in healthy
male subjects
Panel Dose (mg)
AUC0–12ha
(nM/h)
AUC0–a
(nM/h) Cmaxa (nM) C12ha (nM) C24ha (nM) tmaxb (h)
Apparent
terminal t½a
(h)
D (period 1) 1,000 12,517.93
(83.47)
13,000.38
(83.05)
3,865.39
(76.10)
110.88
(105.65)
8.85 (63.05) 3.50
(3.00–4.00)
3.1 (11.4)
E (period 1) 1,000 16,505.14
(87.46)
17,075.08
(86.01)
5,903.18
(77.72)
128.02
(57.51)
10.48 (72.70) 3.00
(2.00–4.02)
3.3 (7.5)
D, E pooled 1,000 14,373.94
(82.53)
14,899.08
(81.61)
4,776.83
(77.60)
119.14
(78.10)
9.63 (65.04) 3.00
(2.00–4.02)
3.2 (9.6)
E (period 2) 1,300 32,250.61
(65.25)
33,151.64
(65.05)
9,198.88
(68.54)
227.87
(67.46)
16.38 (68.56) 3.50
(3.00–6.00)
2.9 (13.2)
E (period 3) 1,300 24,146.87
(83.47)
24,953.89
(82.85)
7,578.83
(83.71)
192.89
(79.74)
12.52 (82.25) 3.00
(3.00–6.00)
3.0 (10.4)
E (periods 2
and 3) pooledc
1,300 28,725.47
(69.66)
29,590.91
(69.26)
8,512.98
(70.23)
213.17
(67.97)
14.71 (70.72) 3.00
(3.00–6.00)
2.9 (11.7)
AUC, area under the curve; C12h, plasma concentration at 12 h postdose; C24h, plasma concentration at 24 h postdose; Cmax, maximum concentration; tmax, time
taken to reach Cmax occurred; t½, elimination half-life.
aGeometric mean and geometric coefficient of variation. bMedian (range). cData for repeat assessments to panel E (treatments E2 and E3) were pooled for overall
pharmacokinetic summary following the 1,300-mg (E2, E3) doses, respectively.
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patients with HCV infection, greater-than-dose-proportional
increases in vaniprevir exposure were reported, with higher
doses being associated with improved antiviral efficacy.14
Lawitz et al.14 reported that in patients with HCV GT1 infec-
tion, tmax ranged between 1 and 3 h, t1/2 was 4–9 h, and
AUC0–12 and Cmax ARs ranged from 1.3–1.8. Similar to the
present study 2, steady-state levels were achieved by day
2 with twice-daily dosing, whereas accumulation was not
evident in patients receiving vaniprevir once daily (AUC0–12
andCmax ratios of 0.88–1.2). Based on PK/pharmacodynamic
correlation analysis in this monotherapy study, there was no
particular association between decline in HCV RNA and any
single vaniprevir PK parameter with the day 8 dose. AUC,
Cmax, and Ctrough were each similarly predictive of virologic
response. Vaniprevir PKs have also been shown to increase
in a greater-than-dose-proportional manner in patients with
HCV infection receiving combination therapy with peginter-
feron and ribavirin.15 At vaniprevir doses of 300 and 600 mg
b.i.d., AUC0–24 values were 5.15 and 23.36 μm·h, respec-
tively, and Cmax and AUC ARs were 1.2–1.8. Collectively,
these studies indicate that the trends in vaniprevir PKs are
generally similar in healthy volunteers and in patients with
HCV infection when administered as monotherapy or in com-
bination with peginterferon and ribavirin.
In conclusion, the data yielded by this study support the
administration of twice-daily vaniprevir in combination with
peginterferon and ribavirin for the treatment of patients with
HCV infection. Based on the cumulative efficacy, safety, PK
data, and data from the vaniprevir development program, a
dose of 300 mg b.i.d. is approved for the treatment of chronic
HCV infection in Japanese patients.9,19
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